Alnylam Pharmaceuticals, INC Form 4 insider transactions

Pushkal Garg, CMO & EVP of Development & Medical Affairs at Alnylam Pharmaceuticals, reports the acquisition of restricted stock units and stock options, along with adjustments to existing holdings.

Jeffrey V. Poulton, EVP and CFO of Alnylam Pharmaceuticals, reports the acquisition of restricted stock units and stock options.

Alnylam Pharmaceuticals CEO Yvonne Greenstreet reports acquisition of restricted stock units and stock options, along with disposition of common stock.

Director Phillip A. Sharp exercised stock options and sold shares of Alnylam Pharmaceuticals on February 29, 2024, under a pre-arranged trading plan.

Tolga Tanguler, Executive VP and Chief Commercial Officer of Alnylam Pharmaceuticals, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Jeffrey Poulton, EVP and CFO of Alnylam Pharmaceuticals, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Alnylam Pharmaceuticals CEO Yvonne Greenstreet reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Pushkal Garg, CMO & EVP of Development & Medical Affairs at Alnylam Pharmaceuticals, reports the sale of company stock to cover tax obligations after restricted stock units vested.

Indrani Franchini, EVP, CLO & Secretary of Alnylam Pharmaceuticals, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.